Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.
BACKGROUND: Multiple sclerosis results from T-cell-dependent inflammatory demyelination of the central nervous system. Our objective was long-term suppression of inflammation with short-term monoclonal antibody treatment. METHODS: We depleted 95% of circulating lymphocytes in 27 patients with multi...
Main Authors: | Coles, A, Wing, M, Smith, S, Coraddu, F, Greer, S, Taylor, C, Weetman, A, Hale, G, Chatterjee, V, Waldmann, H, Compston, A |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado: |
1999
|
Títulos similares
-
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.
por: Coles, A, et al.
Publicado: (1999) -
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.
por: Coles, A, et al.
Publicado: (2006) -
Monoclonal antibodies as agents to reinduce tolerance in autoimmunity.
por: Waldmann, H, et al.
Publicado: (1992) -
CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
por: Lim, S, et al.
Publicado: (1993) -
Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.
por: Moreau, T, et al.
Publicado: (1996)